HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoff, S. J. Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Hoff, S. J. Articles by Johnson, D. H.

The Annals of Thoracic Surgery, Vol 56, 282-286, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma

SJ Hoff, JR Stewart, JL Sawyers, MJ Murray, WH Merrill, RB Adkins and DH Johnson
Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection. There were four deaths during chemotherapy, and 7 patients had a decline in condition or were denied operation. Fifty-six patients have come to operation, and 1 awaits resection. Twenty-two patients had transhiatal esophagectomy and 29 patients had esophagogastrostomy with a combined abdominal and right thoracic approach. Five patients did not undergo resection at operation. There was one hospital death (2%). A complete response to preoperative therapy was seen in 12 patients (21%): 5 of 20 with squamous cancer (25%) and 7 of 36 with adenocarcinoma (19%). Average follow-up is 19 months. Median survival in these patients after entrance in the protocol is 24 months. Actuarial survival at 12, 18, and 24 months is 72% (confidence limits, 66% and 78%), 53% (confidence limits, 46% and 60%), and 51% (confidence limits, 44% and 58%). Significantly better survival was associated with adenocarcinoma (p = 0.041). There is no survival advantage based on complete response to preoperative therapy. This neoadjuvant regimen is effective in patients with squamous carcinoma and adenocarcinoma. These preliminary results demonstrate an improved median and actuarial survival compared with historical controls in 137 patients operated on between 1966 and 1985 at our institution.

This article has been cited by other articles:

				M. Tachibana, S. Kinugasa, N. Hirahara, and H. Yoshimura Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 427 - 431. [Abstract] [Full Text] [PDF]

				J.-L. Lee, S. I. Park, S.-B. Kim, H.-Y. Jung, G. H. Lee, J.-H. Kim, H.-Y. Song, K.-J. Cho, W.-K. Kim, J.-S. Lee, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma Ann. Onc., June 1, 2004; 15(6): 947 - 954. [Abstract] [Full Text] [PDF]

				C. E. Avendano, P. A. Flume, G. A. Silvestri, L. B. King, and C. E. Reed Pulmonary complications after esophagectomy Ann. Thorac. Surg., March 1, 2002; 73(3): 922 - 926. [Abstract] [Full Text] [PDF]

				J. I. Lew, W. E. Gooding, U. Ribeiro Jr, A. V. Safatle-Ribeiro, and M. C. Posner Long-term Survival Following Induction Chemoradiotherapy and Esophagectomy for Esophageal Carcinoma Arch Surg, July 1, 2001; 136(7): 737 - 742. [Abstract] [Full Text] [PDF]

				M. Yasunaga, Y. Tabira, K. Nakano, S. Iida, N. Ichimaru, N. Nagamoto, and T. Sakaguchi Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Ann. Thorac. Surg., November 1, 2000; 70(5): 1634 - 1640. [Abstract] [Full Text] [PDF]

				S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart Prognosis of Adenocarcinoma Arising in Barrett's Esophagus Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181. [Abstract] [Full Text] [PDF]

				D. R. Jones, F. C. Detterbeck, T. M. Egan, L. A. Parker Jr, S. A. Bernard, and J. E. Tepper Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus Ann. Thorac. Surg., July 1, 1997; 64(1): 185 - 192. [Abstract] [Full Text]

				T. N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T. P.J. Hennessy A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma N. Engl. J. Med., August 15, 1996; 335(7): 462 - 467. [Abstract] [Full Text] [PDF]

				K. S. Naunheim, P. J. Petruska, T. S. Roy, J. M. Schlueter, H. Kim, and A. E. Baue Multimodality Therapy for Adenocarcinoma of the Esophagus Ann. Thorac. Surg., May 1, 1995; 59(5): 1085 - 1090. [Abstract] [Full Text]